

HR 4385

Responsibility in Drug Advertising Act of 2017

Congress: 115 (2017–2019, Ended)

Chamber: House

Policy Area: Health

Introduced: Nov 14, 2017

Current Status: Referred to the Subcommittee on Health.

Latest Action: Referred to the Subcommittee on Health. (Nov 17, 2017)

Official Text: <https://www.congress.gov/bill/115th-congress/house-bill/4385>

Sponsor

Name: Rep. DeLauro, Rosa L. [D-CT-3]

Party: Democratic • **State:** CT • **Chamber:** House

Cosponsors

No cosponsors are listed for this bill.

Committee Activity

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Referred to	Nov 17, 2017

Subjects & Policy Tags

Policy Area:

Health

Related Bills

No related bills are listed.

Summary (as of Nov 14, 2017)

Responsibility in Drug Advertising Act of 2017

This bill amends the Federal Food, Drug, and Cosmetic Act to prohibit direct-to-consumer advertising of a drug in the first three years after the drug's approval. The Food and Drug Administration may: (1) waive the third year of this prohibition for a drug if direct-to-consumer advertising of the drug would have an affirmative value to public health, or (2) extend the prohibition if the drug has significant adverse health effects.

Actions Timeline

- **Nov 17, 2017:** Referred to the Subcommittee on Health.
- **Nov 14, 2017:** Introduced in House
- **Nov 14, 2017:** Referred to the House Committee on Energy and Commerce.